Insider Trading Alert - EXAC, FORM And FIX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 21, 2015, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $233.20 to $1,180,446,250.00.

Highlighted Stocks Traded by Insiders:

Exactech (EXAC) - FREE Research Report

Locander William B, who is Director at Exactech, sold 3,350 shares at $21.50 on May 21, 2015. Following this transaction, the Director owned 3,264 shares meaning that the stake was reduced by 50.65% with the 3,350-share transaction.

The shares most recently traded at $21.19, down $0.31, or 1.46% since the insider transaction. Historical insider transactions for Exactech go as follows:

  • 4-Week # shares bought: 738
  • 4-Week # shares sold: 2,200
  • 12-Week # shares bought: 738
  • 12-Week # shares sold: 2,200
  • 24-Week # shares bought: 738
  • 24-Week # shares sold: 2,200

The average volume for Exactech has been 43,100 shares per day over the past 30 days. Exactech has a market cap of $298.9 million and is part of the health care sector and health services industry. Shares are down 9.16% year-to-date as of the close of trading on Thursday.

Exactech, Inc. develops, manufactures, markets, distributes, and sells orthopedic implant devices, related surgical instrumentation, and biologic services to hospitals and physicians in the United States and internationally. The company has a P/E ratio of 18.3. Currently, there is 1 analyst who rates Exactech a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXAC - FREE

TheStreet Quant Ratings rates Exactech as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Exactech Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

This Little-Known Orthopedic-Device Stock Is Delivering Huge Returns

Insider Trading Alert - AGNC, EXAC And TRC Traded By Insiders

Insider Trading Alert - DGICA, MEET And EXAC Traded By Insiders

Will A Positive Earnings Report Help Exactech (EXAC) Stock?